Effect of T‑cadherin on the AKT/mTOR signaling pathway, gastric cancer cell cycle, migration and invasion, and its association with patient survival rate

Lin,Jianqing; Chen,Zhiyao; Huang,Zhijun; Chen,Feng; Ye,Zeyi; Lin,Shaoze; Wang,Weidong

doi:10.3892/etm.2019.7350

Effect of T‑cadherin on the AKT/mTOR signaling pathway, gastric cancer cell cycle, migration and invasion, and its association with patient survival rate

Authors:
- Jianqing Lin
- Zhiyao Chen
- Zhijun Huang
- Feng Chen
- Zeyi Ye
- Shaoze Lin
- Weidong Wang
View Affiliations

Affiliations: Department of Surgical Oncology, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China
Published online on: March 6, 2019 https://doi.org/10.3892/etm.2019.7350
Pages: 3607-3613
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is among the most common types of human cancer and is associated with recurrence and metastasis, despite comprehensive surgical and medical treatment. Previous studies observed downregulation of T‑cadherin expression in GC tissues, suggesting that this protein may act as an oncosuppressor. The current study investigated the activity of T‑cadherin in GC tissues. In a follow‑up study of 81 patients with GC, a Kaplan‑Meier analysis of overall survival revealed a strong association of T‑cadherin overexpression with increased overall survival (P<0.01). Furthermore, stable T‑cadherin‑overexpressing cell lines were established from HGC‑27 cells via transfection of a pcDNA3.1‑T‑cadherin plasmid and in vitro growth and cell cycle of these cells were measured using MTT and flow cytometry assays, respectively. MTT assays revealed that proliferation of engineered T‑cadherin‑overexpressing cells was significantly inhibited and flow cytometry demonstrated that T‑cadherin overexpression in HGC‑27 cells induced cell cycle arrest in the G0/G1 phase. Transwell assays demonstrated that T‑cadherin‑overexpressing HGC‑27 cells exhibited reduced invasiveness and metastatic potential. Phosphorylated (p)‑protein kinase B (AKT) and p‑mammalian target of rapamycin (mTOR) protein levels were reduced in T‑cadherin overexpressing HGC‑27 cells, suggesting that the AKT/mTOR signaling pathway was involved in the gastric tumor inhibitory effect of T‑cadherin. Administration of AKT‑activator, insulin‑like growth factor‑1, to T‑cadherin‑overexpressing HGC‑27 cells significantly affected the proliferation phenotype. In conclusion, the current study provided clinical evidence and revealed a potential mechanism supporting that T‑cadherin inhibits gastric tumorigenesis through inhibition of the AKT/mTOR signaling pathway.

View Figures

View References

1	Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL and Inoue M: Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 17:4421–4428. 2011. View Article : Google Scholar : PubMed/NCBI
2	Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:784–789. 2001. View Article : Google Scholar : PubMed/NCBI
3	Zhang Y, Yang J, Wang J, Guo H and Jing N: LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy. Med Oncol. 31:992014. View Article : Google Scholar : PubMed/NCBI
4	Angst BD, Marcozzi C and Magee AI: The cadherin superfamily: Diversity in form and function. J Cell Sci. 114:629–641. 2001.PubMed/NCBI
5	Dasen B, Vlajnic T, Mengus C, Ruiz C, Bubendorf L, Spagnoli G, Wyler S, Erne P, Resink TJ and Philippova M: T-cadherin in prostate cancer: Relationship with cancer progression, differentiation and drug resistance. J Pathol Clin Res. 3:44–57. 2016. View Article : Google Scholar : PubMed/NCBI
6	Philippova M, Joshi M, Kyriakakis E, Pfaff D, Erne P and Resink T: A guide and guard: The many faces of T-cadherin. Cell Signal. 21:1035–1044. 2009. View Article : Google Scholar : PubMed/NCBI
7	Schmalhofer O, Brabletz S and Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
8	Fedor-Chaiken M, Hein PW, Stewart JC, Brackenbury R and Kinch MS: E-cadherin binding modulates EGF receptor activation. Cell Commun Adhes. 10:105–118. 2003. View Article : Google Scholar : PubMed/NCBI
9	Suyama K, Shapiro I, Guttman M and Hazan RB: A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell. 2:301–314. 2002. View Article : Google Scholar : PubMed/NCBI
10	Derycke LD and Bracke ME: N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol. 48:463–476. 2004. View Article : Google Scholar : PubMed/NCBI
11	Tryndyak VP, Beland FA and Pogribny IP: E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer. 126:2575–2583. 2010.PubMed/NCBI
12	Ivanov D, Philippova M, Allenspach R, Erne P and Resink T: T-cadherin upregulation correlates with cell-cycle progression and promotes proliferation of vascular cells. Cardiovasc Res. 64:132–143. 2004. View Article : Google Scholar : PubMed/NCBI
13	Tang Y, Dai Y and Huo J: Decreased expression of T-cadherin is associated with gastric cancer prognosis. Hepatogastroenterology. 59:1294–1298. 2012.PubMed/NCBI
14	Kong DD, Yang J, Li L, Wang W, Chen YN, Wang SB and Zhou YZ: T-cadherin association with clinicopathological features and prognosis in axillary lymph node-positive breast cancer. Breast Cancer Res Treat. 150:119–126. 2015. View Article : Google Scholar : PubMed/NCBI
15	Wang Z, Wang B, Guo H, Shi G and Hong X: Clinicopathological significance and potential drug target of T-cadherin in NSCLC. Drug Des Devel Ther. 9:207–216. 2014.PubMed/NCBI
16	Ren JZ and Huo JR: Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells. J Med Oncol. 29:915–918. 2012. View Article : Google Scholar
17	Philippova M, Pfaff D, Kyriakakis E, Buechner SA, Iezzi G, Spagnoli GC, Schoenenberger AW, Erne P and Resink TJ: T-cadherin loss promotes experimental metastasis of squamous cell carcinoma. Eur J Cancer. 49:2048–2058. 2013. View Article : Google Scholar : PubMed/NCBI
18	Bosserhoff AK, Ellmann L, Quast AS, Eberle J, Boyle GM and Kuphal S: Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma. Mol Carcinog. 53:635–647. 2014.PubMed/NCBI
19	Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD and Gazdar AF: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 61:4556–4560. 2001.PubMed/NCBI
20	Wang XD, Wang BE, Soriano R, Zha J, Zhang Z, Modrusan Z, Cunha GR and Gao WQ: Expression profiling of the mouse prostate after castration and hormone replacement: Implication of H-cadherin in prostate tumorigenesis. Differentiation. 75:219–234. 2007. View Article : Google Scholar : PubMed/NCBI
21	Takeuchi T, Misaki A, Liang SB, Tachibana A, Hayashi N, Sonobe H and Ohtsuki Y: Expression of T-cadherin (CDH13, H-Cadherin) in human brain and its characteristics as a negative growth regulator of epidermal growth factor in neuroblastoma cells. J Neurochem. 74:1489–1497. 2000. View Article : Google Scholar : PubMed/NCBI
22	Lee SW: H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med. 2:776–782. 1996. View Article : Google Scholar : PubMed/NCBI
23	Takeuchi T, Misaki A, Chen BK and Ohtsuki Y: H-cadherin expression in breast cancer. Histopathology. 35:87–88. 1999. View Article : Google Scholar : PubMed/NCBI
24	Lin J, Chen Z, Huang Z, Chen F, Ye Z, Lin S and Wang W: Upregulation of T-cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro. Exp Ther Med. 14:4194–4200. 2017.PubMed/NCBI
25	Wei B, Shi H, Lu X, Shi A, Cheng Y and Dong L: Association between the expression of T-cadherin and vascular endothelial growth factor and the prognosis of patients with gastric cancer. Mol Med Rep. 12:2075–2081. 2015. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Chan DW, Lee JMF, Chan PC and Ng IO: Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells. Int J Cancer. 123:1043–1052. 2008. View Article : Google Scholar : PubMed/NCBI
28	Adachi Y, Takeuchi T, Nagayama T and Furihata M: T-cadherin modulates tumor-associated molecules in gallbladder cancer cells. Cancer Invest. 28:120–126. 2010. View Article : Google Scholar : PubMed/NCBI
29	Lin Y, Sun G, Liu X, Chen Y and Zhang C: Clinical significance of T-cadherin tissue expression in patients with bladder transitional cell carcinoma. Urol Int. 86:340–345. 2011. View Article : Google Scholar : PubMed/NCBI
30	Lin YL, Xie PG and Ma JG: Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non-muscle-invasive bladder cancer. Med Sci Monit. 20:1572–1577. 2014. View Article : Google Scholar : PubMed/NCBI
31	Lin YL, He ZK, Li ZG and Guan TY: Downregulation of CDH13 expression promotes invasiveness of bladder transitional cell carcinoma. Urol Int. 90:225–232. 2012. View Article : Google Scholar : PubMed/NCBI
32	Fujishima Y, Maeda N, Matsuda K, Masuda S, Mori T, Fukuda S, Sekimoto R, Yamaoka M, Obata Y, Kita S, et al: Adiponectin association with T-cadherin protects against neointima proliferation and atherosclerosis. FASEB J. 31:1571–1583. 2017. View Article : Google Scholar : PubMed/NCBI
33	Kong DD, Wang MH, Yang J, Li L, Wang W, Wang SB and Zhou YZ: T-cadherin is associated with prognosis in triple-negative breast cancer. Oncology letters. 14:2975–2981. 2017. View Article : Google Scholar : PubMed/NCBI
34	Riou P, Saffroy R, Chenailler C, Franc B, Gentile C, Rubinstein E, Resink T, Debuire B, Piatier-Tonneau D and Lemoine A: Expression of T-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma. FASEB J. 20:2291–2301. 2006. View Article : Google Scholar : PubMed/NCBI
35	Yan Q, Zhang ZF, Chen XP, Gutmann DH, Xiong M, Xiao ZY and Huang ZY: Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma. Int J Oncol. 32:1057–1063. 2008.PubMed/NCBI
36	Huang ZY, Wu Y, Hedrick N and Gutmann DH: T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21(CIP1/WAF1) expression. Mol Cell Biol. 23:566–578. 2003. View Article : Google Scholar : PubMed/NCBI
37	Akagi T and Kimoto T: Human cell line (HGC-27) derived from the metastatic lymph node of gastric cancer. Acta Medica Okayama. 30:215–219. 1976.PubMed/NCBI
38	Brown GT and Murray GI: Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 237:227–281. 2015. View Article : Google Scholar
39	Hebbard LW, Garlatti M, Young LJ, Cardiff RD, Oshima RG and Ranscht B: T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res. 68:1407–1416. 2008. View Article : Google Scholar : PubMed/NCBI
40	Claudio F: Targeting the PI3K/AKT/mTOR pathway in prostate cancer development and progression: Insight to therapy. Clin Cancer Drugs. 20:R83–R99. 2016.
41	Ewald F, Nörz D, Grottke A, Bach J, Herzberger C, Hofmann BT, Nashan B and Jücker M: Vertical targeting of AKT and mTOR as well as dual targeting of AKT and MEK signaling is synergistic in hepatocellular carcinoma. J Cancer. 6:1195–1205. 2015. View Article : Google Scholar : PubMed/NCBI